Association of partial T2-FLAIR mismatch sign and isocitrate dehydrogenase mutation in WHO grade 4 gliomas: results from the ReSPOND consortium.
Astrocytoma
Glioblastoma
Isocitrate dehydrogenase
Magnetic resonance imaging
T2-FLAIR mismatch
Journal
Neuroradiology
ISSN: 1432-1920
Titre abrégé: Neuroradiology
Pays: Germany
ID NLM: 1302751
Informations de publication
Date de publication:
Sep 2023
Sep 2023
Historique:
received:
14
04
2023
accepted:
07
07
2023
medline:
16
8
2023
pubmed:
20
7
2023
entrez:
19
7
2023
Statut:
ppublish
Résumé
While the T2-FLAIR mismatch sign is highly specific for isocitrate dehydrogenase (IDH)-mutant, 1p/19q-noncodeleted astrocytomas among lower-grade gliomas, its utility in WHO grade 4 gliomas is not well-studied. We derived the partial T2-FLAIR mismatch sign as an imaging biomarker for IDH mutation in WHO grade 4 gliomas. Preoperative MRI scans of adult WHO grade 4 glioma patients (n = 2165) from the multi-institutional ReSPOND (Radiomics Signatures for PrecisiON Diagnostics) consortium were analyzed. Diagnostic performance of the partial T2-FLAIR mismatch sign was evaluated. Subset analyses were performed to assess associations of imaging markers with overall survival (OS). One hundred twenty-one (5.6%) of 2165 grade 4 gliomas were IDH-mutant. Partial T2-FLAIR mismatch was present in 40 (1.8%) cases, 32 of which were IDH-mutant, yielding 26.4% sensitivity, 99.6% specificity, 80.0% positive predictive value, and 95.8% negative predictive value. Multivariate logistic regression demonstrated IDH mutation was significantly associated with partial T2-FLAIR mismatch (odds ratio [OR] 5.715, 95% CI [1.896, 17.221], p = 0.002), younger age (OR 0.911 [0.895, 0.927], p < 0.001), tumor centered in frontal lobe (OR 3.842, [2.361, 6.251], p < 0.001), absence of multicentricity (OR 0.173, [0.049, 0.612], p = 0.007), and presence of cystic (OR 6.596, [3.023, 14.391], p < 0.001) or non-enhancing solid components (OR 6.069, [3.371, 10.928], p < 0.001). Multivariate Cox analysis demonstrated cystic components (p = 0.024) and non-enhancing solid components (p = 0.003) were associated with longer OS, while older age (p < 0.001), frontal lobe center (p = 0.008), multifocality (p < 0.001), and multicentricity (p < 0.001) were associated with shorter OS. Partial T2-FLAIR mismatch sign is highly specific for IDH mutation in WHO grade 4 gliomas.
Identifiants
pubmed: 37468750
doi: 10.1007/s00234-023-03196-9
pii: 10.1007/s00234-023-03196-9
doi:
Substances chimiques
Isocitrate Dehydrogenase
EC 1.1.1.41
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1343-1352Subventions
Organisme : NCI NIH HHS
ID : R01CA269948
Pays : United States
Organisme : NCI NIH HHS
ID : R01CA269948
Pays : United States
Investigateurs
Stephen J Bagley
(SJ)
Michel Bilello
(M)
Steven Brem
(S)
Ujjwal Baid
(U)
Arati S Desai
(AS)
Robert A Lustig
(RA)
Elizabeth Mamourian
(E)
Anahita Fathi Kazerooni
(AF)
Jose A Garcia
(JA)
Donald M O'Rourke
(DM)
Zev A Binder
(ZA)
Mikhail Milchenko
(M)
Arash Nazeri
(A)
Aris Sotiras
(A)
Murat Ak
(M)
Jaume Capellades
(J)
Josep Puig
(J)
Sung Soo Ahn
(SS)
Jong Hee Chang
(JH)
Seung-Koo Lee
(SK)
Yae Won Park
(YW)
Vachan Vadmal
(V)
Kristin A Waite
(KA)
Sree Gongala
(S)
Alysha Chelliah
(A)
Golestan Karami
(G)
Gregory S Alexander
(GS)
Ayesha S Ali
(AS)
Spencer Liem
(S)
Joseph Lombardo
(J)
Gaurav Shukla
(G)
Muhammad Sharif
(M)
Lisa R Rogers
(LR)
William Taylor
(W)
Santiago Cepeda
(S)
Aikaterini Kotrotsou
(A)
Hassan Fathallah-Shaykh
(H)
Orazio Santo Santonocito
(OS)
Anna Luisa Di Stefano
(AL)
Aaron M Rulseh
(AM)
Yuji Matsumoto
(Y)
Kimberley Alexander
(K)
Laveniya Satgunaseelan
(L)
Benedikt Wiestler
(B)
Rao P Gullapalli
(RP)
Elias R Melhem
(ER)
Graeme F Woodworth
(GF)
Peter I Kamel
(PI)
Victor M Perez-Garcia
(VM)
Alekos Vamvakas
(A)
Yiannis Tsougos
(Y)
Pablo Valdes
(P)
Pallavi Tiwari
(P)
Mariam Aboian
(M)
Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Louis DN, Perry A, Wesseling P et al (2021) The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro Oncol 23(8):1231–1251
doi: 10.1093/neuonc/noab106
pubmed: 34185076
pmcid: 8328013
Parsons DW, Jones S, Zhang X et al (2008) An integrated genomic analysis of human glioblastoma multiforme. Science 321(5897):1807–1812
doi: 10.1126/science.1164382
pubmed: 18772396
pmcid: 2820389
Beiko J, Suki D, Hess KR et al (2014) IDH1 mutant malignant astrocytomas are more amenable to surgical resection and have a survival benefit associated with maximal surgical resection. Neuro Oncol 16(1):81–91
doi: 10.1093/neuonc/not159
pubmed: 24305719
Patel SH, Poisson LM, Brat DJ et al (2017) T2-FLAIR mismatch, an imaging biomarker for IDH and 1p/19q status in lower-grade gliomas: a TCGA/TCIA project. Clin Cancer Res 23(20):6078–6085
doi: 10.1158/1078-0432.CCR-17-0560
pubmed: 28751449
Broen MPG, Smits M, Wijnenga MMJ et al (2018) The T2-FLAIR mismatch sign as an imaging marker for non-enhancing IDH-mutant, 1p/19q-intact lower-grade glioma: a validation study. Neuro Oncol 20(10):1393–1399
doi: 10.1093/neuonc/noy048
pubmed: 29590424
pmcid: 6120363
Jain R, Johnson DR, Patel SH et al (2020) “Real world” use of a highly reliable imaging sign: “T2-FLAIR mismatch” for identification of IDH mutant astrocytomas. Neuro Oncol 22(7):936–943
doi: 10.1093/neuonc/noaa041
pubmed: 32064507
pmcid: 7339896
Do YA, Cho SJ, Choi BS et al (2022) Predictive accuracy of T2-FLAIR mismatch sign for the IDH-mutant, 1p/19q noncodeleted low-grade glioma: an updated systematic review and meta-analysis. Neurooncol Adv 4(1):vdac010
pubmed: 35198981
pmcid: 8859831
Han Z, Chen Q, Zhang L, et al. (2022) Radiogenomic association between the T2-FLAIR mismatch sign and IDH mutation status in adult patients with lower-grade gliomas: an updated systematic review and meta-analysis. Eur Radiol
Foltyn M, Nieto Taborda KN, Neuberger U et al (2020) T2/FLAIR-mismatch sign for noninvasive detection of IDH-mutant 1p/19q non-codeleted gliomas: validity and pathophysiology. Neurooncol Adv 2(1):vdaa004
pubmed: 32642675
pmcid: 7212872
Patel SH, Batchala PP, Muttikkal TJE et al (2021) Fluid attenuation in non-contrast-enhancing tumor (nCET): an MRI Marker for Isocitrate Dehydrogenase (IDH) mutation in Glioblastoma. J Neurooncol 152(3):523–531
doi: 10.1007/s11060-021-03720-y
pubmed: 33661425
Davatzikos C, Barnholtz-Sloan JS, Bakas S et al (2020) AI-based prognostic imaging biomarkers for precision neuro-oncology: the ReSPOND consortium. Neuro Oncol 22(6):886–888
doi: 10.1093/neuonc/noaa045
pubmed: 32152622
pmcid: 7283022
Menze BH, Jakab A, Bauer S et al (2015) The multimodal brain tumor image segmentation benchmark (BRATS). IEEE Trans Med Imaging 34(10):1993–2024
doi: 10.1109/TMI.2014.2377694
pubmed: 25494501
Pati S, Baid U, Edwards B et al (2022) Federated learning enables big data for rare cancer boundary detection. Nat Commun 13(1):7346
doi: 10.1038/s41467-022-33407-5
pubmed: 36470898
pmcid: 9722782
Rohlfing T, Zahr NM, Sullivan EV, Pfefferbaum A (2010) The SRI24 multichannel atlas of normal adult human brain structure. Hum Brain Mapp 31(5):798–819
doi: 10.1002/hbm.20906
pubmed: 20017133
Lasocki A, Gaillard F (2019) Non-contrast-enhancing tumor: a new frontier in glioblastoma research. AJNR Am J Neuroradiol 40(5):758–765
doi: 10.3174/ajnr.A6025
pubmed: 30948373
pmcid: 7053910
VASARI Research Project. https://wiki.cancerimagingarchive.net/display/Public/VASARI+Research+Project . Accessed 8/17/2022.
Chang K, Bai HX, Zhou H et al (2018) Residual convolutional neural network for the determination of IDH status in low- and high-grade gliomas from MR imaging. Clin Cancer Res 24(5):1073–1081
doi: 10.1158/1078-0432.CCR-17-2236
pubmed: 29167275
Choi YS, Bae S, Chang JH et al (2021) Fully automated hybrid approach to predict the IDH mutation status of gliomas via deep learning and radiomics. Neuro Oncol 23(2):304–313
doi: 10.1093/neuonc/noaa177
pubmed: 32706862
Jian A, Jang K, Manuguerra M, Liu S, Magnussen J, Di Ieva A (2021) Machine learning for the prediction of molecular markers in glioma on magnetic resonance imaging: a systematic review and meta-analysis. Neurosurgery 89(1):31–44
doi: 10.1093/neuros/nyab103
pubmed: 33826716
Calabrese E, Rudie JD, Rauschecker AM et al (2022) Combining radiomics and deep convolutional neural network features from preoperative MRI for predicting clinically relevant genetic biomarkers in glioblastoma. Neurooncol Adv 4(1):vdac060
pubmed: 35611269
pmcid: 9122791
Mohammed S, Ravikumar V, Warner E et al (2022) Quantifying T2-FLAIR mismatch using geographically weighted regression and predicting molecular status in lower-grade gliomas. AJNR Am J Neuroradiol 43(1):33–39
doi: 10.3174/ajnr.A7341
pubmed: 34764084
pmcid: 8757555
Pope WBSJ, Perlina A, Villablanca JP, Mischel PS, Cloughesy TF (2005) MR Imaging correlates of survival in patients with high-grade gliomas. AJNR Am J Neuroradiol 26:2466–2474
pubmed: 16286386
pmcid: 7976216
Lasocki A, Gaillard F, Tacey M, Drummond K, Stuckey S (2016) Incidence and prognostic significance of non-enhancing cortical signal abnormality in glioblastoma. J Med Imaging Radiat Oncol 60(1):66–73
doi: 10.1111/1754-9485.12421
pubmed: 26597591
Carrillo JA, Lai A, Nghiemphu PL et al (2012) Relationship between tumor enhancement, edema, IDH1 mutational status, MGMT promoter methylation, and survival in glioblastoma. AJNR Am J Neuroradiol 33(7):1349–1355
doi: 10.3174/ajnr.A2950
pubmed: 22322613
pmcid: 7965490
Han S, Liu Y, Cai SJ et al (2020) IDH mutation in glioma: molecular mechanisms and potential therapeutic targets. Br J Cancer 122(11):1580–1589
doi: 10.1038/s41416-020-0814-x
pubmed: 32291392
pmcid: 7250901
Deguchi S, Oishi T, Mitsuya K et al (2020) Clinicopathological analysis of T2-FLAIR mismatch sign in lower-grade gliomas. Sci Rep 10(1):10113
doi: 10.1038/s41598-020-67244-7
pubmed: 32572107
pmcid: 7308392
Suh CH, Kim HS, Jung SC, Choi CG, Kim SJ (2018) Clinically relevant imaging features for MGMT promoter methylation in multiple glioblastoma studies: a systematic review and meta-analysis. AJNR Am J Neuroradiol 39(8):1439–1445
pubmed: 30002055
pmcid: 7410549
Yogananda CGB, Shah BR, Nalawade SS et al (2021) MRI-based deep-learning method for determining glioma MGMT promoter methylation status. AJNR Am J Neuroradiol 42(5):845–852
doi: 10.3174/ajnr.A7029
pubmed: 33664111
pmcid: 8115363
Kinoshita M, Arita H, Takahashi M et al (2020) Impact of inversion time for FLAIR acquisition on the T2-FLAIR mismatch detectability for IDH-mutant, non-CODEL astrocytomas. Front Oncol 10:596448
doi: 10.3389/fonc.2020.596448
pubmed: 33520709